|January 8, 2013|
|12:12 EDT||AMGN||Amgen cites lack of R&D Tax credit for revised FY12 guidance|
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
|August 27, 2014|
|09:20 EDT||AMGN||FDA grants Amgen priority review designation for ivabradine|
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
|August 26, 2014|
|11:21 EDT||AMGN||Amgen added to short term buy list at Deutsche Bank|
Subscribe for More Information
|August 25, 2014|
|16:17 EDT||AMGN||Western Digital CFO Leyden to retire, Olivier Leonetti to succeed |
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
|August 19, 2014|
|05:11 EDT||AMGN||Gamida Cell announces investment, option agreement with Novartis |
Subscribe for More Information
|August 18, 2014|
|17:25 EDT||AMGN||Amgen announces AMG 416 study met its primary and all secondary endpoints |
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, SHPT, in patients with chronic kidney disease,CKD, receiving hemodialysis, met its primary and all secondary endpoints. "The results from this second Phase 3 study help to confirm that AMG 416 could become an important new treatment option for dialysis patients with secondary hyperparathyroidism," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite the variety of options available for the treatment of this disease, an unmet need remains for an intravenous therapy that can be administered along with hemodialysis. We look forward to sharing results of a head-to-head study evaluating AMG 416 compared to cinacalcet next year."
|August 15, 2014|
|06:54 EDT||AMGN||Amgen shares should 'grind higher' this year, says RBC Capital|
RBC Capital expects Amgen shares to "grind higher" this year driven by a greater appreciation of pipeline programs, the Analyst Day on October 28, an expected filing of the PCSK-9 program soon, and positive Ph iiB anti-CGRP migraine data expected year-end. Shares are Outperform rated.
|August 14, 2014|
|12:01 EDT||AMGN||Third Point gives quarterly update on stakes|
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
|11:52 EDT||AMGN||Third Point discloses new stakes in Finisar, Amgen, Ally Financial|